Search Results

Centauri Therapeutics Limited, an immunotherapy company focused on the treatment of infectious diseases, announced three senior appointments: Dr Jennifer Schneider as Chief Executive Officer, Dr Helen Bright as Vice President of Research & Development, and Professor David Roblin FRCP FMedSci as Chair of the Board of Directors.

Galaxy Medical announced that it received the CE Mark for its CENTAURI Pulsed Electric Field System and launched its commercial program.

Centauri Therapeutics Limited, an immunotherapy company founded by Animatrix Founders LLP and focused on the treatment of infectious diseases, announced the close of its £24 million GBP Series A investment round.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrythmias, announced the acquisition of Galvanize Therapeutics’ Electrophysiology Technology division.

Centauri Therapeutics, an immunotherapy company active in oncology and infectious diseases, announces that it will attend the following scientific and investor conferences

Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero Therapeutics is looking to extend its cash runway while it focuses on other assets in its pipeline.

Following two layoffs in less than three months, Viracta Therapeutics may have around 18 employees left to advance its efforts to bring lead product candidate nana-val to market.

Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand its new modality pipeline to ensure long-term business sustainability.